Patents Assigned to Takara Bio, Inc.
  • Publication number: 20220235375
    Abstract: A method for producing a nucleic acid-encapsulated adeno-associated virus (AAV) hollow particle, comprising the following steps: (1) preparing a linear nucleic acid fragment comprising a sequence for A region and a sequence for D? region in an AAV inverted terminal repeat (ITR) (i.e., an AD sequence) or a sequence complementary to the AD sequence and a target gene sequence; (2) introducing the nucleic acid fragment prepared in step (1) into a cell capable of producing an AAV hollow particle; and (3) culturing the cell obtained in step (2).
    Type: Application
    Filed: July 2, 2020
    Publication date: July 28, 2022
    Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, TAKARA BIO INC.
    Inventors: Takashi OKADA, Junichi MINENO, Hideto CHONO
  • Publication number: 20220162637
    Abstract: The present invention provides a nucleic acid which encodes an adeno-associated virus (AAV) capsid protein mutant that contains a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID Nos. 15 to 62 or a peptide comprising an amino acid sequence produced by substituting, deleting, inserting and/or adding one or several amino acid residues in an amino acid sequence selected from the group consisting of SEQ ID Nos. 15 to 62; DNA comprising the nucleic acid; a cell harboring the DNA; and a method for producing the cell.
    Type: Application
    Filed: April 23, 2020
    Publication date: May 26, 2022
    Applicant: TAKARA BIO INC.
    Inventors: Toshikazu NISHIE, Fuyuko TAKASHIMA, Tatsuji ENOKI, Junichi MINENO, Yoshinori TANAKA
  • Patent number: 11225643
    Abstract: The present invention relates to a method for producing endothelial cells, including carrying out: (a) inducing a population of mesoderm-lineage cells containing endothelial progenitor cells from pluripotent stem cells without forming an embryoid body; and (b) culturing the population of mesoderm-lineage cells containing endothelial progenitor cells in the presence of RepSox, in this order. According to the present invention, endothelial cells with high quality can be efficiently produced from pluripotent stem cells. The endothelial cells obtained by the method of the present invention are useful for the production of, for example, a myocardial sheet, and expected to be utilized in the treatment of a heart disease. A myocardial sheet can be produced by mixing the endothelial cells obtained by the method of the present invention with myocardial cells and mural cells and culturing the cells.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: January 18, 2022
    Assignee: TAKARA BIO INC.
    Inventors: Yuki Yamamoto, Tatsuji Enoki, Yasuhiro Tosaka, Yoko Yamaguchi, Junichi Mineno
  • Patent number: 11220677
    Abstract: Provided are: a reverse transcriptase mutant including an amino acid mutation at a position corresponding to position 55 of the amino acid sequence of wild-type reverse transcriptase derived from the Moloney murine leukemia virus, wherein the reverse transcriptase mutant is characterized in that the amino acid mutation is a substitution from threonine to another amino acid, and the other amino acid is selected from the group consisting of amino acids having a nonpolar aliphatic side chain and amino acids having a polar acidic functional group side chain; a nucleic acid that encodes the mutant; a method for producing the mutant and the nucleic acid that encodes the mutant; a method for synthesizing cDNA in which the mutant is used; and a composition and kit including the mutant.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 11, 2022
    Assignee: TAKARA BIO INC.
    Inventors: Kazuhiko Ishikawa, Takashi Uemori, Nariaki Takatsu
  • Publication number: 20210277367
    Abstract: Provided are: a reverse transcriptase mutant including an amino acid mutation at a position corresponding to position 55 of the amino acid sequence of wild-type reverse transcriptase derived from the Moloney murine leukemia virus, wherein the reverse transcriptase mutant is characterized in that the amino acid mutation is a substitution from threonine to another amino acid, and the other amino acid is selected from the group consisting of amino acids having a nonpolar aliphatic side chain and amino acids having a polar acidic functional group side chain; a nucleic acid that encodes the mutant; a method for producing the mutant and the nucleic acid that encodes the mutant; a method for synthesizing cDNA in which the mutant is used; and a composition and kit including the mutant.
    Type: Application
    Filed: December 13, 2017
    Publication date: September 9, 2021
    Applicant: TAKARA BIO INC.
    Inventors: Kazuhiko ISHIKAWA, Takashi UEMORI, Nariaki TAKATSU
  • Publication number: 20210254018
    Abstract: Stem cells can be efficiently proliferated by culturing the stem cells in the presence of a novel recombinant fibronectin fragment.
    Type: Application
    Filed: July 28, 2017
    Publication date: August 19, 2021
    Applicant: TAKARA BIO INC.
    Inventors: Tomomi OTSUJI, Toshikazu NISHIE, Risa KATO, Sachiko OKAMOTO, Tatsuji ENOKI, Junichi MINENO
  • Publication number: 20210246173
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 12, 2021
    Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi OKADA, Hironori OKADA, Hiromi KINOH, Tatsuji ENOKI, Toshikazu NISHIE, Junichi MINENO
  • Publication number: 20210222137
    Abstract: Provided are: a DNA polymerase mutant having reverse transcriptase activity, the DNA polymerase mutant including a sequence consisting of twelve specific amino acids A1-A12, wherein the DNA polymerase mutant having reverse transcriptase activity is characterized in that the A3 and/or A10 amino acid is substituted by a basic amino acid residue different from that prior to the introduction of mutation; a kit and a composition including the DNA polymerase; a method for producing the DNA polymerase; and a method for modifying an existing DNA polymerase having reverse transcriptase activity.
    Type: Application
    Filed: July 3, 2019
    Publication date: July 22, 2021
    Applicant: TAKARA BIO INC.
    Inventors: Takashi UEMORI, Hiroyuki MATSUMOTO, Kensuke SAITO, Miwa AKITOMO
  • Patent number: 11046939
    Abstract: The present invention relates to a Thermus aquaticus (Taq) polymerase having a strand displacement activity in which an amino acid residue in a template DNA binding site of the DNA polymerase is substituted with an amino acid to increase a total charge in the site, a nucleic acid encoding the polymerase, a vector containing the nucleic acid, a transformant containing the vector containing the nucleic acid or the nucleic acid, a method for producing the polymerase, a method for amplifying nucleic acids utilizing the polymerase, and a kit containing the polymerase. According to the present invention, a DNA polymerase having a high thermostability, capable of efficiently replicating a long-strand of a template DNA, and having a strong strand displacement activity is provided.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: June 29, 2021
    Assignees: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, TAKARA BIO INC.
    Inventors: Yoshizumi Ishino, Sonoko Ishino, Takeshi Yamagami, Takashi Uemori, Nariaki Takatsu
  • Patent number: 11028131
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 8, 2021
    Assignees: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi Okada, Hironori Okada, Hiromi Kinoh, Tatsuji Enoki, Toshikazu Nishie, Junichi Mineno
  • Publication number: 20210164018
    Abstract: The present invention pertains to: an oligonucleotide preservation method; and a kit comprising an oligonucleotide. The present invention provides a method for stably preserving an oligonucleotide-containing solution by adding a nucleic acid-binding protein to said oligonucleotide-containing solution in advance.
    Type: Application
    Filed: June 6, 2018
    Publication date: June 3, 2021
    Applicant: TAKARA BIO INC.
    Inventors: Miwa AKITOMO, Takashi UEMORI
  • Patent number: 10975415
    Abstract: A polypeptide having a mismatch endonuclease activity of recognizing a mismatch and cleaving the mismatch; a mismatch-specific cleavage reaction using the polypeptide; a method for removing an error in a nucleic acid amplification reaction utilizing the polypeptide; a method for inhibiting the amplification of a nucleic acid comprising a specific nucleotide sequence during a nucleic acid amplification reaction; and a method for detecting a nucleic acid having a single-nucleotide polymorphism mutation utilizing the inhibition method.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: April 13, 2021
    Assignees: TAKARA BIO INC., KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, EDUCATIONAL CORPORATION KANSAI BUNRI SOUGOUGAKUEN
    Inventors: Takashi Uemori, Yoshizumi Ishino, Takehiro Sagara, Sonoko Ishino, Takeshi Yamagami, Tsuyoshi Shirai
  • Publication number: 20210062141
    Abstract: In the present invention, lymphocytes are efficiently grown by culturing lymphocytes in the presence of a novel recombinant fibronectin fragment.
    Type: Application
    Filed: January 24, 2019
    Publication date: March 4, 2021
    Applicant: TAKARA BIO INC.
    Inventors: Tomomi OTSUJI, Yuka HIRASE, Asako HATSUYAMA, Sachiko OKAMOTO, Tatsuji ENOKI, Junichi MINENO
  • Patent number: 10822392
    Abstract: Disclosed herein are chimeric antigen receptors (CARs) comprising an intracellular segment comprising an interleukin receptor chain, a JAK-binding motif, a Signal Transducer and Activator of Transcription (STAT) 5 association motif and/or a CD3? intracellular signaling domain comprising an exogenous STAT3 association motif, as well as cells and 5 compositions comprising said CARs and uses thereof.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: November 3, 2020
    Assignees: University Health Network, Takara Bio Inc.
    Inventors: Shinya Tanaka, Naoto Hirano, Yuki Kagoya
  • Patent number: 10760074
    Abstract: A composition for use in amplifying cDNA synthesized by a reverse transcription reaction and detecting RNA that serves as a template of the reverse transcription reaction, the composition containing a thermostable DNA polymerase, a thermostable ribonuclease H, and an intercalating dye. Since the composition of the present invention can suppress the influences to the nucleic acid amplification reaction by RNA that serves as a template for cDNA synthesis, the composition is useful in the detection of RNA, and more useful in quantification of RNA having a desired sequence by real-time RT-PCR.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: September 1, 2020
    Assignee: TAKARA BIO INC.
    Inventors: Kanako Usui, Takashi Uemori, Hiroyuki Mukai, Ikunoshin Kato
  • Patent number: 10731226
    Abstract: A method for quantification of an adeno-associated virus genome, including the steps of (a) preparing a composition containing a sample, at least one primer pair for use in amplification of only a nucleotide sequence contained in inverted terminal repeats of an adeno-associated virus, and an intercalating dye; (b) performing nucleic acid amplification reaction using the composition prepared in the step (a); and (c) detecting an amplified product obtained in the step (b). The present invention is especially useful in the fields of medicine, gene engineering, and biology.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: August 4, 2020
    Assignee: TAKARA BIO INC.
    Inventors: Tamaki Akashika, Katsuyuki Dodo, Masanari Kitagawa
  • Publication number: 20200071675
    Abstract: The present invention relates to a method for producing endothelial cells, including carrying out: (a) inducing a population of mesoderm-lineage cells containing endothelial progenitor cells from pluripotent stem cells without forming an embryoid body; and (b) culturing the population of mesoderm-lineage cells containing endothelial progenitor cells in the presence of RepSox, in this order. According to the present invention, endothelial cells with high quality can be efficiently produced from pluripotent stem cells. The endothelial cells obtained by the method of the present invention are useful for the production of, for example, a myocardial sheet, and expected to be utilized in the treatment of a heart disease. A myocardial sheet can be produced by mixing the endothelial cells obtained by the method of the present invention with myocardial cells and mural cells and culturing the cells.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 5, 2020
    Applicant: TAKARA BIO INC.
    Inventors: Yuki YAMAMOTO, Tatsuji ENOKI, Yasuhiro TOSAKA, Yoko YAMAGUCHI, Junichi MINENO
  • Publication number: 20200002384
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Application
    Filed: January 29, 2018
    Publication date: January 2, 2020
    Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi OKADA, Hironori OKADA, Hiromi KINOH, Tatsuji ENOKI, Toshikazu NISHIE, Junichi MINENO
  • Patent number: 10415020
    Abstract: Provided is a method for producing non-enveloped viral particles, comprising a step for obtaining a fraction containing non-enveloped viral particles by removing precipitates which are produced in a step for adding a substance which reduces the solubility of proteins under acidic conditions and/or a substance which precipitates under acidic conditions to a neutral or basic sample containing non-enveloped viral particles, and acidifying the sample after the addition of the substance.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: September 17, 2019
    Assignee: TAKARA BIO INC.
    Inventors: Yasuhiro Kawano, Shuohao Huang, Tatsuji Enoki, Masanari Kitagawa
  • Patent number: 10336810
    Abstract: Disclosed herein are chimeric antigen receptors (CARs) comprising an intracellular segment comprising an interleukin receptor chain, a JAK-binding motif, a Signal Transducer and Activator of Transcription (STAT) 5 association motif and/or a CD3? intracellular signaling domain comprising an exogenous STAT3 association motif, as well as cells and 5 compositions comprising said CARs and uses thereof.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: July 2, 2019
    Assignees: University Health Network, Takara Bio Inc.
    Inventors: Shinya Tanaka, Naoto Hirano, Yuki Kagoya